ABSTRACT
Background As a condition of dysconnectivity, schizophrenia spectrum disorders (SSD) are characterized by positive, negative, and cognitive symptoms. To improve these symptoms in SSD, physical exercise interventions show promise. We examined if reductions of functional dysconnectivity following exercise therapy are associated with clinical improvements in SSD and explored potential genetic underpinnings.
Methods The study utilized data from the ESPRIT C3 trial, investigating the effects of aerobic exercise versus flexibility, strengthening, and balance training on different health outcomes in individuals with SSD. Functional dysconnectivity in 23 patients relative to a healthy reference sample, was assessed both pre- and post-intervention. Changes of functional dysconnectivity after exercise and their clinical relevance were evaluated. An imaging transcriptomics approach was used to study the link between changes in functional dysconnectivity and gene expression profiles.
Results We observed substantial reductions of functional dysconnectivity on the whole-brain level linked to enhanced gene expression mainly in oligodendrocytes. With regard to the clinical implications, decreases of dysconnectivity in the default-mode network were associated with improvements in global functioning. Reductions of dysconnectivity within the salience network were linked to improvements in symptom severity. Lastly, reductions of functional dysconnectivity in language regions such as Broca’s area were related to cognitive benefits.
Conclusions Our study supports a recent theory of oligodendrocyte pathology in SSD and suggests that reducing functional dysconnectivity in the default-mode, salience, and language network reflect a potential therapeutic target to improve global functioning, total symptom severity, and cognitive impairments in post-acute SSD.
Trial name: ESPRIT C3
Registry: International Clinical Trials Database, ClinicalTrials.gov Registration number: NCT03466112
URL: https://clinicaltrials.gov/ct2/show/NCT03466112?term=NCT03466112&draw=2&rank=1
Competing Interest Statement
PF is a co-editor of the German (DGPPN) schizophrenia treatment guidelines and a co-author of the WFSBP schizophrenia treatment guidelines; he is on the advisory boards and receives speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter. SW, DK, JS, IM, CA, AS, SS and LR declare no conflicts of interest or financial disclosures relevant to this research.
Funding Statement
The work was supported by the German Federal Ministry of Education and Research (BMBF) through the research network on psychiatric diseases ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments; coordinator: Andreas Meyer-Lindenberg; grant number, 01EE1407E) to PF and AS. Furthermore, the study was supported by the Else Kroener-Fresenius Foundation with the Research College Translational Psychiatry to PF, AS, and IM (Residency/PhD track of the International Max Planck Research School for Translational Psychiatry [IMPRS-TP]). The study was endorsed by the Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung [BMBF]) within the initial phase of the German Center for Mental Health (DZPG) (grant: 01EE2303A, 01EE2303F to PF, AS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by the local ethics committee of the Ludwig-Maximilians-University Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
